Current Use and Trends in Hematopoietic Cell Transplantation in the United States

Abstract

Hematopoietic cell transplantation (HCT) is an established curative treatment for a number of malignant and non-malignant diseases involving the hematopoietic system and some solid tumors. In this report, we provide information about the number of HCT procedures performed in the United States (US) in 2015 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research® (CIBMTR®). We show that the numbers of HCT performed annually continue to increase, the indications for HCT, preferred donor sources and GVHD prophylaxis continue to evolve. We report on general overall survival by indication, disease status at transplant and by transplant type. This report demonstrates a current perspective on transplant activity in the US with focus on recent trends in alternative donors and contemporary transplant practices.

A 14‐year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single‐centre experience

“…1 Their ongoing role in an era of novel therapies has been verified in recent literature. 1 Their ongoing role in an era of novel therapies has been verified in recent literature.…”

“…2 Multiple myeloma (MM) is the most common indication for autologous HSCT. [4][5][6] There are several large registries that collect and report data on transplantation activity, including The Center for International Blood and Marrow Transplant Research (CIBMTR) 1 in the United States, and the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) 7 in Australia and New Zealand. Some individuals with high-risk MM may receive an additional cycle of HDT with a second 'tandem' HSCT, typically occurring within 3 months.…”

Patient‐based prediction algorithm of relapse after allo‐HSCT for acute Leukemia and its usefulness in the decision‐making process using a machine learning approach

“…To improve outcomes, attempts are being made to develop strategies that reduce the risk of relapse. Many technical options are now available for allo‐HSCT . Furthermore, with the establishment of a safer method for elderly patients, the number of patients indicated for allo‐HSCT has increased.…”

Epidemiology and biology of relapse after stem cell transplantation

“…There is little doubt that HCT can now be done more safely, with reported rates of transplant-related mortality decreasing from about 50% in the 1970s to as low as 10% in certain patient groups in the current era. 3,4,5,6,7 According to data from the Center for International Blood and Marrow Transplant Research (CIBMTR), transplant-related events such as graft-versus-host disease, Infection and organ toxicity or second cancers accounted for 30%, 52%, 43%, 63% or 57% of posttransplant deaths in patients receiving autologous, HLA-identical sibling, HLA-mismatched related, unrelated donor or unrelated cord blood HCTs, respectively, for leukemia, multiple myeloma or lymphoma in 2012–13 (Figure 1). Corresponding rates for the proportion of deaths related to relapse were 70%, 48%, 57%, 37% and 43% (Figure 1).…”